Aligos Therapeutics Statistics
Total Valuation
ALGS has a market cap or net worth of $43.15 million. The enterprise value is $16.27 million.
| Market Cap | 43.15M |
| Enterprise Value | 16.27M |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALGS has 6.24 million shares outstanding. The number of shares has increased by 32.81% in one year.
| Current Share Class | 5.44M |
| Shares Outstanding | 6.24M |
| Shares Change (YoY) | +32.81% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 1.88% |
| Owned by Institutions (%) | 20.79% |
| Float | 3.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.37 |
| Forward PS | 4.93 |
| PB Ratio | 1.35 |
| P/TBV Ratio | 1.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.19, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.19 |
| Quick Ratio | 2.05 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -113.59% and return on invested capital (ROIC) is -68.51%.
| Return on Equity (ROE) | -113.59% |
| Return on Assets (ROA) | -49.12% |
| Return on Invested Capital (ROIC) | -68.51% |
| Return on Capital Employed (ROCE) | -207.97% |
| Weighted Average Cost of Capital (WACC) | 15.55% |
| Revenue Per Employee | $384,366 |
| Profits Per Employee | -$926,366 |
| Employee Count | 82 |
| Asset Turnover | 0.31 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ALGS has paid $3.21 million in taxes.
| Income Tax | 3.21M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.01% in the last 52 weeks. The beta is 2.28, so ALGS's price volatility has been higher than the market average.
| Beta (5Y) | 2.28 |
| 52-Week Price Change | -39.01% |
| 50-Day Moving Average | 5.86 |
| 200-Day Moving Average | 7.15 |
| Relative Strength Index (RSI) | 56.85 |
| Average Volume (20 Days) | 139,472 |
Short Selling Information
The latest short interest is 568,056, so 9.10% of the outstanding shares have been sold short.
| Short Interest | 568,056 |
| Short Previous Month | 606,525 |
| Short % of Shares Out | 9.10% |
| Short % of Float | 15.34% |
| Short Ratio (days to cover) | 3.95 |
Income Statement
In the last 12 months, ALGS had revenue of $31.52 million and -$75.96 million in losses. Loss per share was -$7.31.
| Revenue | 31.52M |
| Gross Profit | -56.86M |
| Operating Income | -78.99M |
| Pretax Income | -72.75M |
| Net Income | -75.96M |
| EBITDA | -77.92M |
| EBIT | -78.99M |
| Loss Per Share | -$7.31 |
Balance Sheet
The company has $30.38 million in cash and $3.50 million in debt, with a net cash position of $26.88 million or $4.30 per share.
| Cash & Cash Equivalents | 30.38M |
| Total Debt | 3.50M |
| Net Cash | 26.88M |
| Net Cash Per Share | $4.30 |
| Equity (Book Value) | 31.88M |
| Book Value Per Share | 5.11 |
| Working Capital | 33.78M |
Cash Flow
In the last 12 months, operating cash flow was -$94.17 million and capital expenditures -$355,000, giving a free cash flow of -$94.52 million.
| Operating Cash Flow | -94.17M |
| Capital Expenditures | -355,000 |
| Depreciation & Amortization | 1.08M |
| Net Borrowing | -91,000 |
| Free Cash Flow | -94.52M |
| FCF Per Share | -$15.14 |
Margins
Gross margin is -180.40%, with operating and profit margins of -250.63% and -241.01%.
| Gross Margin | -180.40% |
| Operating Margin | -250.63% |
| Pretax Margin | -230.81% |
| Profit Margin | -241.01% |
| EBITDA Margin | -247.21% |
| EBIT Margin | -250.63% |
| FCF Margin | n/a |
Dividends & Yields
ALGS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.81% |
| Shareholder Yield | n/a |
| Earnings Yield | -176.04% |
| FCF Yield | -219.06% |
Analyst Forecast
The average price target for ALGS is $56.29, which is 714.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $56.29 |
| Price Target Difference | 714.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 231.74% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 19, 2024. It was a reverse split with a ratio of 1:25.
| Last Split Date | Aug 19, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
ALGS has an Altman Z-Score of -16.05 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.05 |
| Piotroski F-Score | 2 |